ATE324589T1 - Verfahren zum screening von verbindungen, die die apoptose modulieren, derart identifizierte verbindungen, sowie verwendung der verbindungen als pharmazeutische agentien - Google Patents

Verfahren zum screening von verbindungen, die die apoptose modulieren, derart identifizierte verbindungen, sowie verwendung der verbindungen als pharmazeutische agentien

Info

Publication number
ATE324589T1
ATE324589T1 AT02290578T AT02290578T ATE324589T1 AT E324589 T1 ATE324589 T1 AT E324589T1 AT 02290578 T AT02290578 T AT 02290578T AT 02290578 T AT02290578 T AT 02290578T AT E324589 T1 ATE324589 T1 AT E324589T1
Authority
AT
Austria
Prior art keywords
compounds
apoptotic
particular cell
identified
screening
Prior art date
Application number
AT02290578T
Other languages
English (en)
Inventor
Alphonse Garcia
Xavier Cayla
Angelita Rebollo
Veronica Ayllon
Aarne Fleischer
Original Assignee
Pasteur Institut
Consejo Superior Investigacion
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Consejo Superior Investigacion, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE324589T1 publication Critical patent/ATE324589T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
AT02290578T 2002-03-07 2002-03-07 Verfahren zum screening von verbindungen, die die apoptose modulieren, derart identifizierte verbindungen, sowie verwendung der verbindungen als pharmazeutische agentien ATE324589T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02290578A EP1343013B1 (de) 2002-03-07 2002-03-07 Verfahren zum Screening von Verbindungen, die die Apoptose modulieren, derart identifizierte Verbindungen, sowie Verwendung der Verbindungen als pharmazeutische Agentien

Publications (1)

Publication Number Publication Date
ATE324589T1 true ATE324589T1 (de) 2006-05-15

Family

ID=27741248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02290578T ATE324589T1 (de) 2002-03-07 2002-03-07 Verfahren zum screening von verbindungen, die die apoptose modulieren, derart identifizierte verbindungen, sowie verwendung der verbindungen als pharmazeutische agentien

Country Status (13)

Country Link
US (2) US7217534B2 (de)
EP (2) EP1343013B1 (de)
JP (1) JP4414231B2 (de)
CN (1) CN100529759C (de)
AT (1) ATE324589T1 (de)
AU (1) AU2003226678B2 (de)
CA (1) CA2478042A1 (de)
CY (1) CY1105513T1 (de)
DE (1) DE60210919T2 (de)
DK (1) DK1343013T3 (de)
ES (1) ES2262765T3 (de)
PT (1) PT1343013E (de)
WO (1) WO2003075015A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881430B1 (fr) * 2005-02-01 2010-10-22 Servier Lab Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
US7897401B2 (en) * 2005-11-29 2011-03-01 University Of Maryland, College Park Control of apoptosis by controlling the propensity of ceramide channel formation
AU2008229648A1 (en) * 2007-03-20 2008-09-25 The Walter And Eliza Hall Institute Of Medical Research Method of screening
HUE034563T2 (en) 2007-08-10 2018-02-28 Vm Discovery Inc Preparations and methods comprising apotheque modulators
CN110446803A (zh) * 2016-11-03 2019-11-12 细胞微系统有限公司 自动收集指定数目的细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3855409A (en) * 1970-04-01 1974-12-17 Schmid Lab Method for treating hypercholesterolemia
JP2002532553A (ja) * 1998-12-21 2002-10-02 インケイサ．ソシエダ アノニマ 有害な胃腸副作用を引き起こさない有力な抗炎症剤としてのエーテルリゾリン脂質の使用
JP2003506071A (ja) * 1999-05-28 2003-02-18 アポプトシス テクノロジー，アイエヌシー． アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法
AU2460601A (en) * 1999-12-27 2001-07-09 La Jolla Institute For Allergy Methods for identifying agents capable of modulating protein kinase c theta (pkctheta) activity
WO2002066954A2 (en) * 2001-02-16 2002-08-29 Arbor Vita Corporation Pdz domain interactions and lipid rafts

Also Published As

Publication number Publication date
PT1343013E (pt) 2006-09-29
DK1343013T3 (da) 2006-08-21
JP4414231B2 (ja) 2010-02-10
ES2262765T3 (es) 2006-12-01
WO2003075015A2 (en) 2003-09-12
JP2005518813A (ja) 2005-06-30
CY1105513T1 (el) 2010-04-28
CA2478042A1 (en) 2003-09-12
AU2003226678B2 (en) 2009-12-10
DE60210919D1 (de) 2006-06-01
CN100529759C (zh) 2009-08-19
DE60210919T2 (de) 2007-05-10
US20070184435A1 (en) 2007-08-09
EP1343013B1 (de) 2006-04-26
US20060040331A1 (en) 2006-02-23
WO2003075015A3 (en) 2003-12-24
AU2003226678A1 (en) 2003-09-16
CN1650169A (zh) 2005-08-03
EP1343013A1 (de) 2003-09-10
EP1481250A2 (de) 2004-12-01
US7217534B2 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
WO2003078965A3 (en) System and method for measurement of a response of localized cellular compartments
DE69925362D1 (de) Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
ATE412891T1 (de) Verbessertes toxizität-screening verfahren
DE602004024815D1 (de) Kapsel für die bauindustrie
NZ603648A (en) Methods of purifying polypeptides
WO1994015958A3 (en) Peptide inhibitors of cell adhesion
FR2858410B1 (fr) Procede de determination des contraintes, deformations, endommagement de pieces constituees d'un materiau solide.
IT8320417A0 (it) Apparecchiatura per il compattamento di materiale di scarto, quale rottame relativamente minuto, rifiuti e simili.
WO2004071795A3 (en) Hard tonneau cover
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
ATE332207T1 (de) Maschine zum thermischen schneiden von werkstücken insbesondere mittels laser
ATE324589T1 (de) Verfahren zum screening von verbindungen, die die apoptose modulieren, derart identifizierte verbindungen, sowie verwendung der verbindungen als pharmazeutische agentien
DE60318706D1 (de) Marker für stammzellen und dessen verwendung
DE60322882D1 (de) T zell-subpopulation zur regelung der darmimmunität
DE60209150D1 (de) Dichtungsystem für elektrolysezelle
GB0220553D0 (en) Method andapparatus for determining the viability of eggs
NZ551828A (en) A method of cell isolating a homogenous population of mammary stem cells using specific cell surface marker proteins
AU2005244081A8 (en) T-cell death-inducing epitopes
DK178588D0 (da) Chromogene forbindelser, fremstilling deraf og anvendelse som enzymsubstrater
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.
EP1141703A4 (de) Verfahren zum bestimmen eines erhöhten risikos einer frau ein "down-syndrom" zu tragen
WO2005030804A3 (en) A method of modulating cell survival, differentiation and/or synaptic plasticity
AU2003215108A1 (en) Apparatus for machining composite material test specimens
AU2003298160A8 (en) High-throughput screening method for identifying active substances by means of co-cultivation
ATE403863T1 (de) Verfahren zum nachweis von intrazellulären atp und/oder genexpression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1343013

Country of ref document: EP